Cel-sci selects ergomed as cro as it gears up for confirmatory fda registration study of multikine® in head and neck cancer

Vienna, va.--(business wire)---- $cvm #multikine--cel-sci selects ergomed as cro as it gears up for confirmatory fda registration study of multikine in head and neck cancer.

SCI Ratings Summary

SCI Quant Ranking